About the Authors
- Manish A. Shah
-
* E-mail: mas9313@med.cornell.edu
Affiliation The Weill Cornell Medical College/New York–Presbyterian Hospital, New York, New York, United States of America
- Zev A. Wainberg
-
Affiliation University of California Los Angeles, Los Angeles, California, United States of America
- Daniel V. T. Catenacci
-
Affiliation University of Chicago, Chicago, Illinois, United States of America
- Howard S. Hochster
-
Affiliation Yale University, New Haven, Connecticut, United States of America
- James Ford
-
Affiliation Stanford University, Stanford, California, United States of America
- Pamela Kunz
-
Affiliation Stanford University, Stanford, California, United States of America
- Fa-Chyi Lee
-
Affiliation University of New Mexico, Albuquerque, New Mexico, United States of America
- Howard Kallender
-
Affiliation GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Fabiola Cecchi
-
Affiliation Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
- Daniel C. Rabe
-
Affiliation Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
- Harold Keer
-
Affiliation Exelixis, South San Francisco, California, United States of America
- Anne-Marie Martin
-
Affiliation GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Yuan Liu
-
Affiliation GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Robert Gagnon
-
Affiliation GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Peter Bonate
-
Affiliation GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America
- Li Liu
-
Affiliation GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Tona Gilmer
-
Affiliation GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America
- Donald P. Bottaro
-
Affiliation Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
Competing Interests
Dr. Kallender, Dr. Martin, Dr. Y. Liu, Dr. Gagnon Dr. L. Liu, Dr. Gilmer are employees of, and have equity interest in GlaxoSmithKline. Dr. Keer is an employee of FivePrime Therapeutics Inc. with equity interest in Exelixis. Editorial support in the form of development of draft outline, development of manuscript first draft, assembling tables and figures, collating author comments, copyediting and referencing was provided by Ann Sherwood, PhD of CONNEXION Healthcare, Newtown, PA, and by MediTech Media, Manchester, UK, and was funded by GlaxoSmithKline. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Final approval of manuscript: MAS ZAW DC HH JF PK FCL H. Kallender FC DCR H. Keer AMM YL RG PB LL TG DPB. Conceived and designed the experiments: H. Kallender MAS DPB H. Keer. Performed the experiments: MAS ZAW DC HH JF PK FCL DPB PB LL TG. Analyzed the data: DPB DCR FC MAS H. Kallender AMM YL RG PB LL TG. Contributed reagents/materials/analysis tools: DPB H. Kallender MAS. Wrote the paper: MAS H. Kallender DPB.